SIGN AND RETURN THIS PAGE TO CIRMRT1-01012-1 NOTICE OF GRANT AWARD CIRM RFA-08-02:Tools & Technologies California Institute for Regenerative Medicine
EX-10.47 3 ex10-47.htm CIRM GRANT AWARD ex10-47.htm
EXHIBIT 10.47
SIGN AND RETURN THIS PAGE TO CIRM RT1-01012-1
NOTICE OF GRANT AWARD – CIRM RFA-08-02: Tools & Technologies
California Institute for Regenerative Medicine
Issue Date: April 1, 2009
| Grant Number: | RT1-01012-1 | Budget Period: | Annual as of 4/1/2009 |
| Grantee Name: | VistaGen Therapeutics, Inc. | ||
| Grantee ID: | PR-Y0002A-SF | Project Period Start: | 4/1/2009 |
| Principal Investigator: | Dr. Kristina C. Bonham | Project Period End: | 3/31/2011 |
| Project Title: | Development of an hES Cell-Based Assay System for Hepatocyte Differentiation Studies and Predictive Toxicology Drug Screening | ||
| Authorized Organizational Official and Address: Ralph Snodgrass, PhD CEO VistaGen Therapeutics, Inc. 384 Oyster Point Blvd #8 South San Francisco, CA 94080 | Official and Address to Receive Payments: Cell Biology Attn: Kristina Bonham, PhD VistaGen Therapeutics, Inc. 384 Oyster Point Blvd #8 South San Francisco, CA 94080 |
The California Institute for Regenerative Medicine (CIRM) hereby awards a grant in the amount of $971,558 to be disbursed over a total period of 2 years to VistaGen Therapeutics, Inc. (Grantee ID PR-Y0002A-SF) in support of the above referenced project. This award is pursuant to the California Stem Cell Research and Cures Act (Health and Safety Code section 125290.10 et. seq.) and is subject to terms and conditions referenced below. (Capitalized terms are defined in the CIRM Grants Administration Policy for Academic and Non-Profit Institutions (GAP), a copy of which may be found on the CIRM website at: http://www.cirm.ca.aov/reg/pdf/req100500 policv.pdf.)
In accepting this Grant, the Grantee warrants to CIRM that any funds expended underthe award will be for the purposes set forth in the approved application and agrees to comply with all applicable CIRM regulations. See Item II (page 3) below.
To accept this Grant, the Principal Investigator and Authorized Organizational Official must sign and return this Notice of Grant Award (NGA) to CIRM within 45 days of the issue date. Payment will be issued only after the signed NGA is received by CIRM. Grant funds will be sent to the organization's address listed above under Official and Address to Receive Payments unless an updated address is provided in the box below. If the applicant cannot accept the award, including the legal obligation to perform in accordance with the provisions of this NGA, it should notify CIRM immediately.
If you have any questions about this award, please contact the CIRM staff referenced on page 3.
| /s/ Marie Csete Marie Csete, MD, Ph.D. Chief Scientific Officer California Instituted for Regenerative Medicine | Updated Address to Receive Payments: |
AWARD ACCEPTANCE: The Principal Investigator and Authorized Organizational Official must sign below and return the entire NGA to CIRM to accept the Grant award.
| Principal Investigator | Authorized Organizational Official | |
| Name | Dr. Kristina C. Bonham | Ralph Snodgrass, PhD |
| Signature | /s/ Kristina C. Bonham | /s/ H. Ralph Snodgrass |
| Date | 4/8/09 | 4/7/09 |
SIGN AND RETURN TO CIRM
RT1-01012-1
NOTICE OF GRANT AWARD
California Institute for Regenerative Medicine
I. AWARD DATA:
AWARD DETAIL (U.S. Dollars):
| Year l | Year 2 | |
| Direct Project Costs | ||
| Personnel (Non -Trainee) Costs | $252,001 | $253,127 |
| Trainee Costs | ||
| Travel | $9,800 | $10,000 |
| Supplies | $30,000 | $28,800 |
| Equipment | $ 0 | $ 0 |
| Consultants/Subcontracts | $8,000 | $8,000 |
| Total Project Costs | $299,801 | $299,927 |
| Facilities Costs | ||
| Facilities Costs - Category A | $ 52,465 | $ 52,487 |
| Facilities Costs - Category B | $ 52,465 | $ 52,487 |
| Indirect Costs | ||
| Indirect Costs | $80,946 | $80,980 |
| APPROVED BUDGET TOTAL | $485,677 | $485,881 |
QUARTERLY INSTALLMENTS ON GRANT PAYMENTS
Payments will be made in quarterly installments, issued at the beginning of each quarter. Quarters will be tied to the project start date. The final quarterly installment will be held until completion of Close-Out.
*Any interest accrued by the Grantee from the Grant payment must be used for the CIRM Tools & Technologies Program.
PROGRESS REPORTS SCHEDULE
| Year 1 | Year 2 | |
| Programmatic Report | 2/1/2010 | 2/1/2011 |
| Financial Report | 7/1/2010 | 7/1/2011 |
| Close-Out Report | n/a | 7/1/2011 |
RT1-01012-1
NOTICE OF GRANT AWARD
California Institute for Regenerative Medicine
II. TERMS AND CONDITIONS
This award is based on the application submitted to CIRM, and as approved by the Independent Citizens' Oversight Committee (ICOC) on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:
| A. | The California Stem Cell Research and Cures Act (Health and Safety Code Section 125290.10 et. seq.) and regulations adopted by the ICOC. |
| B. | The CIRM Interim Grants Administration Policy for For-Profit Organizations (Title 17, California Code of Regulations, Section 100501), CIRM Grants Administration Policy for Academic and Non-Profit Institutions (Title 17, California Code of Regulations, Section 100500), CIRM Intellectual Property Policy and Revenue Sharing Requirements for For-Profit Organizations, the CIRM Medical and Ethical Standards Regulations (Title 17, California Code of Regulations, Sections 100010-1000110), CIRM Use of Fetal Tissue (Title 17, California Code of Regulations, Section 10085), and any subsequently adopted applicable regulations. |
| C. | The terms and requiremenets detailed in RFA 08-02: CIRM Tools and Technologies Awards. |
| D. | Grantee shall not commence work on the K117 hESC line until approval to use this line is granted by the institution’s SCRO committee and documentation of that verifies such approval has been received by CIRM. |
| E. | The timing of the distribution of funds pursuant to this grant shall be contingent upon the availability of funds in the California Stem Cell Research and Cures Fund in the State Treasury, as determined by CIRM in its sole discretion. |
Please check the following website for updated policy documents: http://www.cirm.ca.qov/req/
III. CIRM CONTACTS:
Andrew McFarland, Grants Management Specialist
Phone: ###-###-#### Email: ***@*** Fax: ###-###-####
Sohel Talib, PhD, Scientific Program Officer
Phone: ###-###-#### Email: ***@*** Fax: ###-###-####
The CIRM home page is at http://www.cirm.ca.gov
CIRM Mailing Address:
California Institute for Regenerative Medicine
Attn: Andrew McFarland, Grants Management Specialist
210 King Street
San Francisco, CA 94107
RT1-01012-1
Budget Adjustments
Note 1: None
Note 2:
Note 3:
| Year 1 Requested Amount | Year 1 Approved Budget | Year 2 Requested Amount | Year 2 Approved Budget | Year 2 Expenditure Report | Total Approved Budget |
Exhibit 10.47
